Nitroderm

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitroderm

Property Description
Active ingredient Nitroglycerin (Glyceryl trinitrate)
Form Transdermal System (Patch)
Pharmacological class Vasodilator, Organic Nitrate
Common use Prophylaxis of Angina Pectoris
Origin Synthetic

1. Definition, Classification, and Composition

The medicine known as Nitroderm is the trade name for the Nitroglycerin Transdermal System, a prescription-only medicine for adult patients. The active ingredient is Nitroglycerin, or Glyceryl trinitrate (GTN), a synthetic compound belonging to the organic nitrates pharmacological class. This single-ingredient product is categorized as a Vasodilator and an Antianginal agent by authoritative regulatory bodies.

2. The Role of the Transdermal Patch (Matrix System)

Nitroderm utilizes a Transdermal patch (Matrix patch) as its dosage form, which is applied topically to the skin for systemic absorption. This patch design is engineered for continuous controlled release of the medication over many hours. This method is clinically recognized for its ability to maintain stable therapeutic concentrations, a key feature that differentiates it from rapid-acting nitrates.

3. General Purpose of Nitroderm

The fundamental therapeutic purpose of the Nitroglycerin Transdermal System is the prophylaxis, or prevention, of episodes of Angina Pectoris associated with Coronary Artery Disease. The drug’s mechanism involves direct action on vascular smooth muscle, causing vasodilation (vessel widening). This effect effectively reduces the heart's workload by decreasing the volume and pressure it handles (preload and afterload), thereby helping to prevent ischemic chest pain.

Regulatory References

  1. DailyMed FDA

What side effects are possible with Nitroderm?

Possible Side Effects and Safety Information

The safety profile of the Nitroglycerin Transdermal System is based on regulatory classifications of adverse effects documented during clinical use and post-marketing surveillance. Adverse reactions are grouped by frequency and the body system affected (System-Organ Class or SOC), consistent with official regulatory documentation.

Frequency and Organ System Classification of Adverse Reactions

A Very Common adverse reaction, affecting more than 1 in 10 patients, is headache. This effect is typically most frequently observed at the start of treatment.

Common reactions, affecting between 1 in 100 and 1 in 10 patients, span several systems, including Nervous System Disorders (dizziness), Cardiac Disorders (tachycardia), Gastrointestinal Disorders (nausea and vomiting), and Skin and Subcutaneous Tissue Disorders, which involve local reactions such as application site erythema (redness) and pruritus (itching).

Rare effects, reported in fewer than 1 in 1,000 patients, include syncope (fainting) and circulatory collapse. A Very Rare but serious effect reported is methemoglobinemia, a blood disorder. An important safety pattern associated with continuous long-term administration is the potential development of tolerance (diminished pharmacological response).


Serious Safety Constraints and Population-Specific Notes

The use of this system is restricted in patients with pre-existing conditions that pose significant safety constraints. These conditions include severe anemia, acute circulatory failure (shock or collapse), and conditions involving increased intracranial pressure. Specific heart conditions, such as pericardial tamponade or restrictive cardiomyopathy, also serve as strict contraindications.

Population-Specific Considerations: Caution is recommended for older adults due to an increased regulatory concern for the risk of orthostatic hypotension (dizziness upon standing). Use in pediatric patients is not recommended due to a lack of established safety data.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdose of the Nitroglycerin Transdermal System (e.g., Nitroderm) is based strictly on documentation from government regulatory authorities.

Overdose manifestations primarily result from profound vasodilation, which may lead to severe systemic and neurological effects.

Documented Overdose Manifestations

System Officially Documented Signs/Symptoms
Cardiovascular Severe hypotension (low blood pressure), tachycardia (fast heart rate), bradycardia, and heart block
Systemic/Neurological Severe throbbing headache, confusion, syncope (fainting), seizures, coma, profuse sweating, and paralysis
Gastrointestinal Nausea, vomiting, and bloody diarrhea

Serious outcomes documented in regulatory labeling include collapse, severe Methemoglobinemia, and the risk of death.

Required Emergency Actions

In the event of a suspected overdose, the first action required is the immediate removal of the transdermal system(s). There is no specific antagonist to the vasodilatory effects of nitroglycerin, although Methylene Blue is the specific treatment listed for symptomatic Methemoglobinemia.

Immediate medical help must be sought if the person has collapsed, had a seizure, has trouble breathing (dyspnea), or can't be awakened. Contacting emergency medical services or a Poison Control Center is required. Treatment is supportive, often involving elevation of the patient's legs and intravenous fluid infusion to manage severe hypotension, with careful clinical monitoring required.

Therapeutic Uses of Nitroderm

What Nitroderm Treats: Main Uses and Benefits

Nitroderm (nitroglycerin transdermal system) is a transdermal patch commonly used to provide long-term, supportive treatment that is applied in addressing symptom clusters that may become intense or disruptive in patients with coronary artery disease, specifically those experiencing chest pain, or angina.

The patch is considered relevant for easing symptoms associated with acute or episodic changes. The therapeutic domain is applied when conditions involve episodic or fluctuating manifestations, when symptoms interfere with daily functioning, or in contexts involving heightened systemic burden. This approach contributes to improved comfort and supports general well-being during symptomatic phases.

“It may assist with maintaining functional stability and eases the overall symptom burden.”

The transdermal system is applied in addressing the long-term risk of these episodic or fluctuating manifestations and is not used to treat an acute or sudden angina attack once it has begun.

Quick Fact: Relief for symptoms that interfere with daily functioning

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Nitroderm?

Eligibility for the Nitroglycerin Transdermal System is strictly defined by regulatory documents, distinguishing between approved populations, those requiring caution, and groups who must not use the medicine.

Approved Population: The medicine is indicated for use only in adult patients for the prevention of angina pectoris.


Absolute Contraindications (Must Not Use):

Contraindicated Group
Patients with known hypersensitivity to nitroglycerin, other nitrates, or transdermal patch components.
Patients receiving Phosphodiesterase type 5 (PDE-5) inhibitors (e.g., sildenafil) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat).
Patients with acute circulatory failure associated with marked hypotension or shock.
Patients with raised intracranial pressure or Hypertrophic Obstructive Cardiomyopathy (HOCM).

Use with Restrictions or Caution:

Restricted Group
Pediatric Patients: Safety and effectiveness have not been established.
Elderly Patients: Use requires caution due to increased susceptibility to severe hypotension.
Pregnancy/Lactation: Use is conditional as data are insufficient or it is not known if the drug is present in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for the Nitroglycerin Transdermal System is defined by pharmacodynamic effects that prohibit or restrict co-administration with specific medicinal products and substances. All interactions described are based on official regulatory documentation.

Contraindicated Combinations

Co-administration with several classes of medicine is formally prohibited. Phosphodiesterase type 5 (PDE5) Inhibitors, including sildenafil and tadalafil, are contraindicated due to the documented risk of severe, potentially fatal hypotension. The same restriction applies to Soluble Guanylate Cyclase (sGC) Stimulators, such as riociguat, which also carry a high risk of profound blood pressure reduction. Additionally, co-use with Ergot Alkaloids (e.g., ergotamine) is contraindicated because these agents can antagonize and decrease the intended effects of nitroglycerin.


Pharmacodynamic Potentiation

Other substances and medicinal product categories may exhibit additive or potentiating effects. The vasodilating effects of the transdermal system may significantly potentiate the blood pressure-lowering effect when co-administered with other Antihypertensives (such as calcium channel blockers, beta-blockers, and diuretics), Tricyclic Antidepressants, or Major Tranquilisers. Alcohol is also documented as exhibiting additive vasodilatory effects. The co-use of calcium channel blockers, in particular, has been associated with reports of marked symptomatic orthostatic hypotension.

Mechanism of Action

Mechanism of Action

The mechanism of Nitroderm begins within vascular smooth muscle cells where the enzyme mitochondrial aldehyde dehydrogenase ( ALDH2) facilitates the bioactivation of the drug, converting it into the signaling molecule nitric oxide ( NO). This NO then acts as an agonist, engaging the intracellular enzyme soluble guanylate cyclase (sGC).

Activation of sGC triggers the cGMP signaling cascade, which leads to the dephosphorylation of myosin light chains and initiates widespread vasodilation, most pronounced in the venous system. By increasing venous capacity, the mechanism lowers the volume of blood returning to the heart (preload). This hemodynamic consequence reduces the heart's pumping effort and overall myocardial oxygen demand.

The function of this mechanism is constrained by nitrate tolerance upon continuous exposure. This loss of effect is mechanistically linked to the functional limitation of the upstream ALDH2 enzyme, which restricts the necessary conversion of the drug into active NO.

Dosage and Administration Information

How to use Nitroderm: Official Administration Guidelines

Nitroderm (nitroglycerin transdermal system) is administered solely via the topical route as a self-adhesive transdermal patch, applied to the intact skin of the upper body or upper arm.


Dosing and Cyclic Schedule

Official guidelines specify that the transdermal system is intended exclusively for the long-term prevention (prophylaxis) and is not to be used for treating an acute anginal episode.

Treatment is initiated with the lowest available patch strength, such as 0.2 mg/hr or 0.4 mg/hr, and may be titrated upward based on prophylactic requirements, with a typical maintenance range up to 0.8 mg/hr in some regimens.

To prevent the development of tolerance, the medication is administered using a cyclic regimen. The patch is applied once daily and is worn for a defined period of 12 to 14 hours, followed by an obligatory 10- to 12-hour nitrate-free interval before a new patch is applied.


Administration Requirements

Procedural Requirement Instruction Population Rule
Patch Preparation Do not cut or trim the patch; apply it whole to a clean, dry, hairless area. Pediatrics: Safety and effectiveness are not established.
Application Site The site must be rotated daily (e.g., upper arm, chest) to avoid skin irritation. Discontinuation: Should be gradual and not abrupt to avoid procedural risks.

These guidelines define the standardized, time-structured approach to using the Nitroglycerin Transdermal System.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nitroderm


Evidence for the Prevention of Angina Pectoris Episodes

Research examined the transdermal system in the context of prophylaxis (managing the likelihood) of episodic chest pain associated with chronic stable coronary artery disease. Research consists mainly of short-term, placebo-controlled trials, often using a crossover design. Researchers examined specific outcomes related to systemic or functional imbalance, such as total exercise duration, changes in the ST-segment depression on an electrocardiogram (ECG), and patient-reported outcomes describing discomfort. The findings describe patterns observed in the studies where the transdermal system was compared against an inactive patch, contributing context on how measured outcomes evolved in the observed populations during the study period.


Durability and Duration of Study Follow-Up

The available data regarding the durability of patterns observed over time summarizes typical observation periods used in clinical evaluation trials. The research explored short-term symptom changes, with intervals typically ranging from single-day (acute) assessments up to intermediate durations of 14 to 30 days. The results apply only to the populations studied and the specific conditions under which they were conducted; long-term effects are not fully established beyond these intermediate trial timeframes.


Key Findings on Study Limitations and Nitrate Tolerance

A key area of research examined understanding the physiological patterns associated with transdermal nitroglycerin use. The most consistent finding was research focused on nitrate tolerance, where the body may lose the measured changes in outcomes related to physiological strain when the patch is applied continuously. Studies explored intermittent application methods explored in research protocols to address this. However, research also describes patterns related to outcomes reflecting daily functioning that may include a change in exercise capacity following patch removal during the defined patch-free interval; this was associated with the term rebound effect. Certainty remains low regarding the full context of this rebound effect outside of specific research settings.


Research in Specific Patient Groups

The research evidence largely stemmed from studies in the labeled population: adults diagnosed with chronic stable angina. The results apply only to the populations studied, which were often small and featured specific enrollment criteria. Data for certain groups remain insufficient. For instance, comparative evidence is lacking for how the findings may relate to all older adults or to patients with a high number of other concurrent conditions that could affect exercise capacity. Limited information is available regarding research outside of the approved adult indication, meaning findings describe group patterns, not personal outcomes.


Evidence Gaps and Areas of Uncertainty

Areas of uncertainty remain. The existing studies provide limited insight into the long-term outcomes and the durability of the observed patterns over multiple years of use. Follow-up durations were limited, and the general applicability of findings to all patients with chronic stable angina may vary significantly. Research does not determine whether an individual will respond similarly or maintain these observed patterns over many years.

Key Studies & References

  1. Nitroglycerin Transdermal System: Drug Label Information (DailyMed FDA)
  2. Nitroglycerin Patch: Drug Information (MedlinePlus NIH)

Frequently Asked Questions (FAQ)

Common questions about Nitroderm (FAQ)


Q: How is Nitroderm different from other common medications for the same purpose?

A: Official information indicates this medicine is a transdermal patch for continuous, long-term prevention, which differs from some other angina treatments taken orally. The patch requires a specific cyclic use schedule—an 'on-and-off' period—to prevent the body from developing tolerance.

Q: Do the effects of Nitroderm last for a full day?

A: No, the effects are not designed to last for a full 24-hour period. The medicine is administered using a cyclic regimen that includes a 10- to 12-hour 'nitrate-free interval' each day. This patch-free time is necessary to prevent the body from developing tolerance (loss of effect).

Q: Are there known long-term effects associated with using Nitroderm?

A: Research follow-up durations for this transdermal system were generally limited, meaning long-term effects beyond intermediate trial timeframes are not fully established. A consistent pattern observed in studies is the potential development of tolerance, where the medicine's effect diminishes with continuous, uninterrupted use.

Q: Is Nitroderm considered safe for older adults to use?

A: Official warnings indicate that caution is recommended for older adults. This is due to regulatory concerns regarding an increased risk of orthostatic hypotension, which is dizziness or lightheadedness upon standing. Information indicates that use requires caution.

Q: Are there official warnings about using Nitroderm during pregnancy?

A: Official documents state that use during pregnancy and lactation is conditional. This is due to a lack of definitive data; it is either insufficient or officially not known if the drug is present in human milk or carries a direct risk to the developing fetus.

Q: Is there substantial research evidence supporting the use of Nitroderm?

A: Research supporting the labeled use consists mainly of short-term, placebo-controlled trials often using a crossover design. These studies examined specific outcomes such as total exercise capacity and changes in the heart's electrical activity (ECG) in the labeled adult population.

Q: How long does it typically take for the effects of Nitroderm to be noticeable?

A: According to the official product information, the antianginal effect of the transdermal system is not rapid. It is typically not to be used for acute anginal attacks, as it generally requires around two hours after application to reach the full preventative therapeutic concentrations in the body.

Q: What over-the-counter pain relievers interact with Nitroderm, according to official documents?

A: Official prescribing information notes documented interactions with certain common over-the-counter pain relievers, including aspirin and acetaminophen. These combinations may carry risks, and regulatory warnings indicate that interactions should be discussed with a healthcare provider beforehand.

Q: Can Nitroderm be used by people with a history of liver issues?

A: Regulatory patient instructions advise that individuals with a history of liver disease or kidney disease should exercise caution. These conditions may affect how the medicine is processed by the body. Regulatory information indicates that patients with a history of these conditions should exercise caution.

Q: What should a person do if they forget to apply Nitroderm?

A: Official patient instructions describe the procedure: if a patch is missed, it can be applied as soon as it is remembered. If it is almost time for your next scheduled application, the missed one is skipped, and two patches should not be applied at the same time.

Q: Does Nitroderm affect a person's ability to drive or operate machinery?

A: Potential side effects of this medicine include dizziness and lightheadedness. Because these effects may affect coordination and judgment, official warnings advise that caution should be used when driving or operating machinery until the patient is certain how the medicine affects their function.

Q: Does using Nitroderm mean a person will become dependent on it?

A: Sudden stopping of organic nitrate medicines, including this transdermal system, has been associated with an increased risk of withdrawal symptoms in certain populations. Official documentation refers to this pattern as the existence of true physical dependence. Discontinuation must follow a gradual process under the direction of a healthcare professional.

Q: What are the general restrictions on physical activity while using Nitroderm?

A: General restrictions on physical activity relate to the potential for the patch to absorb medicine too quickly. Official patient warnings indicate that excessive physical exertion or strenuous exercise should be avoided, as the resulting body heat can significantly increase the absorption of the medication.

Q: Does the official product information for Nitroderm mention interactions with herbal supplements?

A: Official patient instructions indicate that the use of herbal supplements or vitamins should be discussed with a healthcare provider. This is because the potential for undocumented or unknown interactions exists, which could affect the medicine's action.

Q: Why is Nitroderm used on the skin instead of being taken orally?

A: The patch is used for long-term prevention because the active ingredient, nitroglycerin, has an extremely short half-life—around three minutes—when taken orally. The transdermal system is necessary to provide the continuous, controlled release required to maintain stable therapeutic concentrations for long-term prevention.

Q: Is Nitroderm ever used in combination with other treatments for the same condition?

A: Yes, the transdermal system may be used along with other antianginal agents for the prevention of chest pain. Official information states that it can be used in conjunction with other treatments, such as beta-blockers and certain calcium channel blockers.

Q: Are the side effects of Nitroderm generally reported as mild or severe?

A: Official documentation classifies side effects primarily by their frequency, rather than a general statement of mild or severe. Side effects span a wide range, from very common and generally manageable effects like headache to rare but serious reported effects such as circulatory collapse.

Q: Does Nitroderm interact with common medications for high blood pressure?

A: Yes, official documents state that co-administration with other Antihypertensives (such as beta-blockers and diuretics) can significantly potentiate the blood pressure-lowering effect. This interaction can lead to symptomatic orthostatic hypotension, which is dizziness caused by a drop in blood pressure when standing up.

Q: What kind of monitoring by a doctor is needed while using Nitroderm?

A: Regular patient monitoring is recommended, according to official prescribing information. This typically includes checking blood pressure and heart rate to monitor for the risk of hypotension (low blood pressure) and to ensure proper use of the medication.

Q: Is it necessary to avoid heat or sun exposure while using Nitroderm?

A: Yes. Official patient warnings indicate that external heat sources should be avoided while wearing the patch. Exposure to heat, such as from sun bathing, saunas, heating pads, hot tubs, or heat lamps, can significantly increase the absorption of the medicine.

Q: What is the longest period of time a person can use Nitroderm according to studies?

A: The available research studies focused on short-term and intermediate durations, with follow-up periods typically ranging up to 30 days. The findings do not determine the durability or safety of the medicine over multiple years of continuous use.

Q: Why is Nitroderm described as a 'patch' and not a tablet?

A: The transdermal patch design is engineered for the continuous, controlled release of the medication. This systemic absorption through the skin helps maintain the stable therapeutic concentrations over many hours, which is necessary for the long-term prevention of chest pain.

Q: How quickly does the effect wear off once the Nitroderm patch is removed?

A: The required 10- to 12-hour patch-free interval is specifically designed to allow the effects of the medicine to wear off completely. Research also describes patterns related to a 'rebound effect' linked to the decline of action during this interval.

How should Nitroderm be stored and disposed of?

Storage Requirements

Nitroglycerin transdermal patches must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The product must be kept in its original individual sealed pouch until immediate use and should be stored away from excess heat and moisture; the patches must not be refrigerated or frozen. All medication must be kept out of the sight and reach of children.

Disposal Instructions

Due to the presence of residual active medicine, both used and unused patches can pose a hazard to children and pets. The official instructions for used patches require them to be folded in half with the sticky surfaces pressed together before disposal. The patches must be discarded safely, away from children and pets. Unused or expired medication should be disposed of via a drug take-back program or official household disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitroderm found in:

A-Z Index: